CGC
NYSECanopy Growth Corporation
SectorHealth CareIndustry Medicinal Chemicals and Botanical Products
Price$0.87-0.09 (-8.89%)
2026-07-072026-10-07
News · 26 weeks53+160%
2026-04-122026-10-04
Mix2990d
- SEC Filings11(38%)
- Other7(24%)
- Insider7(24%)
- Earnings2(7%)
- Leadership2(7%)
Latest news
25 items- SECSEC Form DEFA14A filed by Canopy Growth CorporationDEFA14A - Canopy Growth Corp (0001737927) (Filer)
- INSIDERDirector Yanofsky Theresa sold $13,828 worth of shares (14,920 units at $0.93), decreasing direct ownership by 10% to 131,495 units (SEC Form 4) to satisfy withholding obligation4 - Canopy Growth Corp (0001737927) (Issuer)
- INSIDERDirector Lazzarato David Angelo sold $20,742 worth of shares (22,380 units at $0.93), decreasing direct ownership by 11% to 189,479 units (SEC Form 4) to satisfy tax liability4 - Canopy Growth Corp (0001737927) (Issuer)
- INSIDERDirector Bayern Joseph sold $2,869 worth of shares (3,096 units at $0.93), decreasing direct ownership by 2% to 142,031 units (SEC Form 4) to cover withholding tax4 - Canopy Growth Corp (0001737927) (Issuer)
- INSIDERDirector Atkins M Shan sold $2,869 worth of shares (3,096 units at $0.93), decreasing direct ownership by 2% to 143,421 units (SEC Form 4) (for withholding tax)4 - Canopy Growth Corp (0001737927) (Issuer)
- PRCanopy Growth Appoints Sebastian Blöte as Country Manager for GermanyMr. Blöte’s appointment strengthens Canopy Growth’s commercial leadership as it drives growth across its European medical cannabis businessCanopy Growth Corporation ("Canopy Growth", "our", "we" or the "Company") (TSX:WEED) (NASDAQ:CGC), a leading global company committed to bettering lives through cannabis, today announced the appointment of Sebastian Blöte as Country Manager for Germany, effective October 1, 2026.Mr. Blöte will lead Canopy Growth's commercial strategy in Germany, with responsibility for expanding sales and strengthening execution across the market, deepening connections with partners and healthcare professionals, and driving growth to fully capture the significant potentia
- SECSEC Form DEFA14A filed by Canopy Growth CorporationDEFA14A - Canopy Growth Corp (0001737927) (Filer)
- PRCanopy Growth Announces Adjournment of 2026 Annual General and Special Meeting Due to Lack of QuorumAnnual General and Special Meeting of Shareholders of Canopy Growth to reconvene on Friday, October 23, 2026, at 1:00 p.m. ET Shareholders now have until Friday, October 23, 2026, at 9:00 a.m. ET to submit their votes Canopy Growth Corporation ("Canopy Growth", "our", "we" or the "Company") (TSX:WEED) (NASDAQ:CGC), a leading global company committed to bettering lives through cannabis, today announced that, due to the requisite quorum not being present, its Annual General and Special Meeting of shareholders (the "Meeting"), scheduled for Friday, September 25, 2026, at 1:00 p.m. ET via live webcast, was convened and then adjourned. The Meeting will reconvene on Friday, October 23, 2
- PRCanopy Growth Announces Extension of Proxy Voting Deadline for 2026 Annual General and Special MeetingShareholders now have until Friday, September 25, 2026, at 12:00 p.m. ET to submit their votes Shareholders who need assistance can contact Sodali & Co. at 1-833-830-8205 toll free in North America, or 1-289-695-3075 collect outside North America, or by email at CGC@investor.sodali.com Canopy Growth Corporation ("Canopy Growth", "our", "we" or the "Company") (TSX:WEED) (NASDAQ:CGC), a leading global company committed to bettering lives through cannabis, today announced it has extended the proxy voting deadline for its upcoming Annual General and Special Meeting of shareholders (the "Meeting") to 12:00 p.m. ET on Friday, September 25, 2026. The Meeting will be held later the same da
- PRCanopy Growth Expands European Medical Cannabis Supply Into the UKFour Canadian-grown flower strains to be supplied for distribution in the UK medical cannabis market under Spectrum Therapeutics Canopy Growth Corporation ("Canopy Growth", "our", "we" or the "Company") (TSX:WEED) (NASDAQ:CGC), a leading global company committed to bettering lives through cannabis, today announced that it will supply four Canadian-grown medical cannabis flower strains for distribution in the United Kingdom (the "UK"), expanding the reach of its international cannabis business into another European market. The Canadian-grown flower strains will be supplied to GROW Group U.K. Ltd. ("GROW Group"), a manufacturer and distributor of prescribed cannabis-based medicines across
- INSIDEROfficer Stewart Thomas Carlton sold $23,952 worth of shares (25,755 units at $0.93), decreasing direct ownership by 4% to 588,412 units (SEC Form 4) to satisfy withholding tax4 - Canopy Growth Corp (0001737927) (Issuer)
- SECSEC Form DEFA14A filed by Canopy Growth CorporationDEFA14A - Canopy Growth Corp (0001737927) (Filer)
- PRCanopy Growth Reminds Shareholders to Vote Ahead of September 23 DeadlineShareholders are encouraged to vote now ahead of the Company’s Annual General and Special Meeting of shareholders on September 25, 2026 Votes must be submitted by 1:00pm ET on September 23, 2026, to ensure they are counted Shareholders with questions or who need assistance can contact Canopy Growth’s proxy solicitation agent, Sodali & Co. at 1-833-830-8205 toll free in North America, or 1-289-695-3075 collect outside North America, or by email at CGC@investor.sodali.com Canopy Growth Corporation ("Canopy Growth", "our", "we" or the "Company") (TSX:WEED) (NASDAQ:CGC), a leading global company committed to bettering lives through cannabis, today reminds shareholders to vote ahead of
- PRCanopy Growth Broadens Australian Medical Cannabis Portfolio With New Formats and FormulationsNew pastille and all-in-one vape formats, expanded oil and softgel offerings, and new flower SKUs build on international growth momentum Canopy Growth Corporation ("Canopy Growth", "our", "we" or the "Company") (TSX:WEED) (NASDAQ:CGC), a leading global company committed to bettering lives through cannabis, today announced a broadening of its medical cannabis portfolio in Australia across its Spectrum Therapeutics, Spectrum Therapeutics Reserve, 7ACRES, Tweed and Twd. brands. The expansion introduces two new product formats, and new formulations within its existing oil and softgel ranges. "Expanding our product offering in established markets like Australia is central to our internationa
- INSIDEROfficer Gedeon Christelle sold $19,616 worth of shares (13,344 units at $1.47), decreasing direct ownership by 2% to 692,162 units (SEC Form 4) to cover taxes4 - Canopy Growth Corp (0001737927) (Issuer)
- INSIDEROfficer Stewart Thomas Carlton sold $3,280 worth of shares (2,231 units at $1.47), decreasing direct ownership by 0.36% to 614,167 units (SEC Form 4) to satisfy withholding obligation4 - Canopy Growth Corp (0001737927) (Issuer)
- SECSEC Form DEFA14A filed by Canopy Growth CorporationDEFA14A - Canopy Growth Corp (0001737927) (Filer)
- PRCanopy Growth Announces Mailing of Proxy Materials for 2026 Annual General and Special Meeting – Urges Shareholders to Vote NowShareholders are encouraged to vote well in advance of the meeting scheduled on September 25, 2026, at 1:00 PM ET. To ensure that votes are counted, Shareholders must submit their vote no later than 1:00 p.m. ET on September 23, 2026. Canopy Growth shareholders with a 16-digit control number can vote at http://proxyvote.com, or by phone at 1-800-474-7493 (English) or 1-800-474-7501 (French). Many shareholders are also eligible to vote quickly and conveniently over the phone by contacting the Company’s proxy solicitation agent, Sodali & Co. at 1-833-830-8205 toll free in North America or 1-289-695-3075 collect outside North America or by email at CGC@investor.sodali.com Canopy Growth C
- SECSEC Form DEFA14A filed by Canopy Growth CorporationDEFA14A - Canopy Growth Corp (0001737927) (Filer)
- PRCanopy Growth Secures Renewed EU GMP Certification at Kincardine as European Medical Cannabis Business GrowsRenewed certification maintains Kincardine’s role in Canopy Growth’s EU GMP flower supply chain Canopy Growth Corporation ("Canopy Growth", "our", "we" or the "Company") (TSX:WEED) (NASDAQ:CGC), a leading global company committed to bettering lives through cannabis, today announced that its Kincardine, Ontario cultivation facility ("Kincardine") has received renewed European Union Good Manufacturing Practice ("EU GMP") certification from the Regierungspräsidium Tübingen – Leitstelle Arzneimittelüberwachung Baden-Württemberg. With its EU GMP status renewed, Canopy Growth can continue supplying Canadian-grown cannabis from Kincardine to medical cannabis markets across Europe. "This rene
- SECSEC Form DEFA14A filed by Canopy Growth CorporationDEFA14A - Canopy Growth Corp (0001737927) (Filer)
- SECSEC Form DEF 14A filed by Canopy Growth CorporationDEF 14A - Canopy Growth Corp (0001737927) (Filer)
- SECCanopy Growth Corporation filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K - Canopy Growth Corp (0001737927) (Filer)
- SECCanopy Growth Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Canopy Growth Corp (0001737927) (Filer)
- PRCanopy Growth Reports First Quarter Fiscal Year 2027 Financial Results; Delivers 13% Net Revenue Growth with Contributions from All BusinessesNet revenue growth of 22% in Canada medical cannabis, 10% in Canada adult-use cannabis, 10% in international markets cannabis and 6% in Storz & Bickel Adjusted gross margin1 improves to 31% in Q1 FY2027 from 25% in Q1 FY2026 Adjusted EBITDA2 loss narrows by 59% year-over-year Canopy Growth Corporation ("Canopy Growth", "our", "we" or the "Company") (TSX:WEED) (NASDAQ:CGC), a leading global company committed to bettering lives through cannabis, today announced its financial results for the three months ended June 30, 2026 ("Q1 FY2027"). All financial information in this press release is reported in Canadian dollars, unless otherwise indicated. "The renewed focus and strong momentum w
CGC FAQ
6 questionsWhat does Canopy Growth Corporation do?
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flowers, oils and concentrates, and softgel capsules. It offers its products under the Tweed, Quatreau, Deep Space, Spectrum Therapeutics, First & Free, TWD, This Works, BioSteel, DNA Genetics CraftGrow, Tokyo Smoke, DOJA, Van der Pop...Where does CGC stock trade?
Canopy Growth Corporation (CGC) is listed on NYSE.What sector and industry is CGC in?
Canopy Growth Corporation operates in the Health Care sector, Medicinal Chemicals and Botanical Products industry.What are analysts saying about CGC?
Canopy Growth Corporation has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy on 2026-03-27.What companies are similar to CGC?
Notable peers in the same industry include PM (Philip Morris International Inc), BTI (British American Tobacco Industries p.l.c.), MO (Altria Group Inc.), DFTX (Definium Therapeutics Inc.), RGC (Regencell Bioscience Holdings Limited). Compare CGC side-by-side with any of them on Quantisnow.How can I track CGC on Quantisnow?
Quantisnow aggregates Canopy Growth Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CGC to receive live email and push alerts on every new disclosure.